银黄清肺胶囊联合洛匹那韦/利托那韦治疗普通型COVID-19病毒感染的临床疗效及安全性
Effect of Yinghuang Qingfei Capsule and Lopinavir/Ritonavir Treatment in Patients with Mild COVID-19
DOI: 10.12677/TCM.2021.102039, PDF,  被引量    科研立项经费支持
作者: 阎昱升, 汤渝玲：长沙市第一医院呼吸内科，湖南 长沙；屈金艳, 高 尚：湖南安邦制药股份有限公司，湖南 长沙；魏艳蓉, 范伏元：湖南中医药大学第一附属医院，湖南 长沙
关键词: 银黄清肺胶囊；洛匹那韦/利托那韦；COVID-19；超敏C反应蛋白；降钙素原；Yinghuang Qingfei Capsule； Lopinavir/Ritonavir； COVID-19； Hs-CRP； PCT
摘要: 目的：探讨银黄清肺胶囊联合洛匹那韦/利托那韦治疗普通型COVID-19病毒感染的临床疗效及安全性。方法：选取隔离病房收治的普通型COVID-19病毒感染患者40例，按随机数字法，随机分配为对照组20例和治疗组20例，对照组予以洛匹那韦/利托那韦治疗，治疗组在对照组基础上加用银黄清肺胶囊治疗。比较2组临床治愈率、临床症状改善时间、超敏C反应蛋白(hs-CRP)和降钙素原(PCT)含量，以及不良反应发生率。结果：治疗14天后，治疗组退热时间、咳嗽消失时间明显短于对照组(P < 0.05)，且hs-CRP含量明显降低，PCT异常患者全部转变为正常，差异有统计学意义(P < 0.05)。两组总有效率、不良反应发生率比较，差异无统计学意义(P > 0.05)。结论：银黄清肺胶囊联合洛匹那韦/利托那韦治疗普通型COVID-19病毒感染的临床疗效确切，可以缩短患者症状消退时间，改善炎症指标，且安全性较高。
Abstract: Objective: To evaluate the clinical efficacy and safety of Yinghuang Qingfei capsule combined with lopinavir/ritonavir in the treatment of mild COVID-19 virus infection. Methods: Forty patients with mild COVID-19 virus infection admitted to the isolation ward were randomly divided into two groups according to the random number method, 20 patients in the control group and 20 patients in the experimental group. The control group was treated with lopinavir/ritonavir. The experimental group was treated with Yinghuang Qingfei capsule on the basis of the control group. The clinical cure rate, the improvement time of clinical symptoms, the content of high sensitive C-reactive protein (hs-CRP) and procalcitonin (PCT) and the incidence of adverse reactions were compared between the two groups. Results: After 14 days of treatment, the time of fever reduction and cough disappearance in the experimental group was significantly shorter than that in the control group (P < 0.05). And the content of hs-CRP was significantly reduced, and all patients with abnormal PCT turned to normal, the difference was statistically significant (P < 0.05). There was no significant difference in the total effective rate and the incidence of adverse reactions between the two groups (P > 0.05). Conclusion: The clinical efficacy of Yinghuang Qingfei capsule combined with lopinavir/ritonavir in the treatment of mild COVID-19 virus infection is definite, which can shorten the time of symptom resolution in patients and improve inflammation indicators with high safety.
文章引用：阎昱升, 屈金艳, 魏艳蓉, 范伏元, 汤渝玲, 高尚. 银黄清肺胶囊联合洛匹那韦/利托那韦治疗普通型COVID-19病毒感染的临床疗效及安全性[J]. 中医学, 2021, 10(2): 284-290. https://doi.org/10.12677/TCM.2021.102039

参考文献

[1] 赵文明, 宋述慧, 陈梅丽, 邹东, 马利娜, 马英克, 李茹姣, 郝丽丽, 李翠萍, 田东梅, 唐碧霞, 王彦青, 朱军伟, 陈焕新, 章张, 薛勇彪, 鲍一明. 2019新型冠状病毒信息库[J]. 遗传, 2020, 42(2): 212-221.
[2] 王露莹, 陈品儒, 郑国湾, 漆楠, 杨科. 新型冠状病毒检测方法的研究进展[J]. 现代药物与临床, 2020, 35(3): 411-416.
[3] 张诗琬, 喻雪琴, 陈芳, 敬雪明, 梅怡晗, 梅小平. 新型冠状病毒肺炎的研究进展[J]. 山东医药, 2020, 60(13): 110-114.
[4] Guan, W.-J., Ni, Z.-Y., Hu, Y., et al. (2020) Clinical Characteristics of Coronavirus Disease 2019 in China. The New England Journal of Medicine, 382, 1708-1720. [Google Scholar] [CrossRef] 
[5] Smriti, M. (2020) Why Does the Coronavirus Spread So Easily between People? Nature, 579, 183. [Google Scholar] [CrossRef] [PubMed]
[6] 中华预防医学会新型冠状病毒肺炎防控专家组. 新型冠状病毒肺炎流行病学特征的最新认识[J]. 中国病毒病杂志, 2020, 10(2): 81-87.
[7] 高树明, 马英, 杨丰文, 张俊华, 于春泉. 张伯礼: 中医药在防治新型冠状病毒肺炎全过程发挥作用[J]. 天津中医药, 2020, 37(2): 121-124.
[8] 白爽, 李澎, 赵立. 抗病毒与中医药治疗方案变迁——对新型冠状病毒肺炎患者转归趋势的宏观影响[J]. 中国临床药理学杂志, 2020, 36(7): 912-917.
[9] 史锁芳, 刘清泉. 从“江夏方舱中医模式”探讨中医药在新型冠状病毒肺炎治疗中的价值[J]. 江苏中医药, 2020, 52(4): 11-14.
[10] Hu, K., Guan, W.-J., Bi, Y., et al. (2020) Efficacy and Safety of Lianhuaqingwen Capsules, a Repurposed Chinese Herb, in Patients with Coronavirus Disease 2019: A Multicenter, Prospective, Randomized Controlled Trial. Phytomedicine, 2020, Article ID: 153242. [Google Scholar] [CrossRef] [PubMed]
[11] 彭志, 卢芳国, 屈金艳, 李玲, 范伏元, 那婧婧, 李湘兰. 银黄清肺胶囊含药血清体外抗呼吸道合胞病毒实验研究[J]. 湖南中医药大学学报, 2016, 36(2): 40-43.
[12] 李湘兰, 卢芳国, 易登峰, 李玲, 范伏元, 葛资宇, 彭志. 银黄清肺胶囊含药血清体外抗流感病毒实验研究[J]. 中华中医药学刊, 2015, 33(5): 1107-1109.
[13] 邱瑜, 张思, 张妙红. 银黄清肺胶囊对幼龄大鼠流感病毒肺炎的保护作用及机制研究[J]. 中南药学, 2018, 16(9): 1240-1243.
[14] 李妲, 范伏元. 银黄清肺胶囊合头孢西丁治疗社区获得性肺炎的临床观察[J]. 中医药导报, 2015, 21(16): 71-72+75.
[15] 新型冠状病毒感染的肺炎诊疗方案(试行第五版) [J]. 江苏中医药, 2020, 52(2): 96+95.
[16] 李力, 李琦, 程金波, 毛梅, 艾山木, 谭虎, 杨仕明, 胡明冬, 任小宝, 王斌, 张宏雁, 徐迪雄, 毛青, 曹国强. 新型冠状病毒肺炎患者分层治疗与中医辅助治疗方案[J]. 第三军医大学学报, 2020, 42(4): 427-430.
[17] 李修洋, 宋斌, 雷烨, 李青伟, 郑玉娇, 刘文科, 王强, 朱向东, 黄飞剑, 沈仕伟, 周毅德, 杨映映, 张培, 林家冉, 赵林华. 《新型冠状病毒肺炎诊疗方案(试行第六版)》中医诊疗方案解读[J]. 吉林中医药, 2020, 40(6): 701-708.
[18] 唐璇, 佟琳, 郭非非, 唐仕欢, 杨洪军. 基于TCMATCOV平台的常用经典名方治疗新型冠状病毒肺炎潜在作用分析[J]. 中国中药杂志, 2020, 45(13): 3028-3034.
[19] 张云, 杨卉, 何轩辉, 吴广均, 李军. 麻杏石甘汤治疗新冠肺炎细胞因子风暴的网络药理学分析[J]. 世界中医药, 2020, 15(13): 1908-1913.
[20] 陈恩超. 麻杏石甘汤合葶苈大枣泻肺汤加减治疗小儿肺炎的效果[J]. 中国医学创新, 2019, 16(11): 141-144.
[21] 谭亚云, 梁冬. 麻杏石甘汤合葶苈大枣泻肺汤加减辅助治疗社区中老年患者获得性肺炎的疗效分析[J]. 中国实验方剂学杂志, 2016, 22(5): 202-205.
[22] 孙惠敏, 徐锋, 张玲, 魏聪, 陈杰勇, 王秋欣, 贾振华. 连花清咳颗粒治疗轻型、普通型新型冠状病毒肺炎临床疗效观察[J]. 中国实验方剂学杂志, 2020, 26(14): 29-34.
[23] Liu, Y.-P., Li, G.-M., He, J., et al. (2020) Combined Use of the Neutrophil-to-Lymphocyte Ratio and CRP to Predict 7-Day Disease Severity in 84 Hospitalized Patients with COVID-19 Pneumonia: A Retrospective Cohort Study. Annals of Translational Medicine, 8, 635. [Google Scholar] [CrossRef] [PubMed]
[24] Tobias, H., Vindi, J., Chiara, A., et al. (2020) Elevated Levels of IL-6 and CRP Predict the Need for Mechanical Ventilation in COVID-19. The Journal of Allergy and Clinical Immunology, 146, 128-136. [Google Scholar] [CrossRef] [PubMed]
[25] Chen, W., Zheng, K.I., Liu, S.D., et al. (2020) Plasma CRP Level Is Positively Associated with the Severity of COVID-19. Annals of Clinical Microbiology and Antimicrobials, 19, 18. [Google Scholar] [CrossRef] [PubMed]
[26] 白露, 刘泽世, 周柯, 徐修礼. 新型冠状病毒肺炎临床实验室相关检测现状[J/OL]. 检验医学与临床, 2020. http://kns.cnki.net/kcms/detail/50.1167.R.20200323.1709.002.html
[27] 昌仲勇, 杨为斌, 王强, 廖国林. 血清hs-CRP、IL-6、PCT对新型冠状病毒肺炎患者的诊断及预后评估的临床意义[J]. 现代药物与临床, 2020, 35(3): 417-420.
[28] Yu, G.H., Zhang, Y.Q., Ren, W.Q., et al. (2016) Network Pharmacology-Based Identification of Key Pharmacological Pathways of Yin-Huang-Qing-Fei Capsule Acting on Chronic Bronchitis. International Journal of Chronic Obstructive Pulmonary Disease, 11, 85-94. [Google Scholar] [CrossRef] 
[29] 范伏元, 李妲. 银黄清肺胶囊治疗急性气管-支气管炎风热犯肺证60例疗效观察[J]. 中医药导报, 2014, 20(1): 36-37.
[30] 何薇, 李明晖, 苏美霞, 马建永. 银黄清肺胶囊联合左氧氟沙星治疗下呼吸道肺炎支原体感染的临床研究[J]. 中华中医药学刊, 2016, 34(6): 1418-1420.
[31] 蒋牧, 徐旭东, 顾靖华. 银黄清肺胶囊辅助治疗支气管扩张急性加重期临床研究[J]. 新中医, 2019(8): 113-116.
[32] 蔡剑英, 陶学芳. 银黄清肺胶囊治疗COPD急性加重期患者的疗效观察及对血清PCT、CRP水平的影响[J]. 中国中医药科技, 2020, 27(2): 279-280.